David Roman
Stock Analyst at Goldman Sachs
(1.12)
# 1601
Out of 5,270 analysts
31
Total ratings
37.50%
Success rate
15.81%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Teladoc Health | Maintains: Buy | 16 13 | 9.44 | 37.71% | 3 | Mar 3, 2025 | |
Tandem Diabetes Care | Maintains: Neutral | 42 24 | 20.75 | 15.66% | 2 | Mar 3, 2025 | |
Solventum | Maintains: Sell | 63 71 | 80.14 | -11.41% | 4 | Mar 3, 2025 | |
LivaNova | Maintains: Buy | 64 55 | 41.74 | 31.77% | 2 | Mar 3, 2025 | |
Baxter Intl | Reinstates: Buy | 42 | 34.85 | 20.52% | 3 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 91 124 | 108.97 | 13.79% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 58 80 | 68.2 | 17.3% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 384 427 | 394.58 | 8.22% | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 81 90 | 71.41 | 26.03% | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 108 | 104.85 | 3% | 1 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 90 | 104.8 | -14.12% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 500 | 567.1 | -11.83% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 121 | 140.22 | -13.71% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 274 | 228.3 | 20.02% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 129 | 105.33 | 22.47% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Sell | 83 | 94.02 | -11.72% | 1 | May 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 87 | 86.44 | 0.65% | 1 | May 30, 2024 |